

Treatment advances in antiphospholipid syndrome: 2022

Current Opinion in Pharmacology

65, 102212

DOI: [10.1016/j.coph.2022.102212](https://doi.org/10.1016/j.coph.2022.102212)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Severe thrombotic complications secondary to antiphospholipid syndrome and undiagnosed systemic lupus erythematosus. <i>Cmaj</i> , 2022, 194, E1243-E1247.	2.0	2
2	Primary and secondary antiphospholipid syndrome characteristics in an Egyptian cohort. <i>Egyptian Rheumatologist</i> , 2022, 44, 373-376.	1.0	1
3	Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS) Tj ETQq0 0 0 rgBT /Overlock 10Tf 50 657		
4	Complications thrombotiques graves du syndrome des antiphospholipides et dâ€™un lupus Ã©rythÃ©mateux dissÃ©minÃ© non diagnostiquÃ©. <i>Cmaj</i> , 2023, 195, E43-E48.	2.0	0
5	An update on the biologics for the treatment of antiphospholipid syndrome. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
6	The ABCs of antiphospholipid syndrome. <i>Archives of Rheumatology</i> , 2023, 38, 163-173.	0.9	2
7	Antiphospholipid antibody carriers and patients with quiescent antiphospholipid syndrome show persistent subclinical complement activation. <i>Rheumatology</i> , 0, , .	1.9	0
8	Efficacy and safety of long-term use of low molecular weight heparins in patients with systemic lupus erythematosus and antiphospholipid syndrome. <i>Sovremennaya Revmatologiya</i> , 2023, 17, 15-21.	0.5	1
9	High percentage of blood-based T-cell receptor gamma V9-JP recombinations associated with amyotrophic lateral sclerosis: extensive retention of the JP KKIK amino acid motif. <i>Exploration of Immunology</i> , 0, , 598-603.	0.3	0
10	Anticoagulant and non-anticoagulant therapy in thrombotic antiphospholipid syndrome: old drugs and new treatment targets. <i>Rheumatology</i> , 2024, 63, S196-SI106.	1.9	1